138 related articles for article (PubMed ID: 27826027)
1. Evaluation of Pentravan
Bourdon F; Lecoeur M; Leconte L; Ultré V; Kouach M; Odou P; Vaccher C; Foulon C
Int J Pharm; 2016 Dec; 515(1-2):774-787. PubMed ID: 27826027
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
3. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
4. Effect of formulation pH on transdermal penetration of antiemetics formulated in poloxamer lecithin organogel.
Woodall R; Arnold JJ; McKay D; Asbill CS
Int J Pharm Compd; 2013; 17(3):247-53. PubMed ID: 24046940
[TBL] [Abstract][Full Text] [Related]
5. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Dranitsaris G; Mazzarello S; Smith S; Vandermeer L; Bouganim N; Clemons M
Support Care Cancer; 2016 Apr; 24(4):1563-9. PubMed ID: 26381427
[TBL] [Abstract][Full Text] [Related]
6. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Kim HJ; Shin SW; Song EK; Lee NR; Kim JS; Ahn JS; Yun HJ; Cho YH; Park KU; Kim SY; Jang JS; Kim SW; Lee HW; Lee SR; Kim YS; Lee SN; Ko YH; Kim HJ; Kang JH
Oncologist; 2015 Dec; 20(12):1440-7. PubMed ID: 26512046
[TBL] [Abstract][Full Text] [Related]
7. A validated micellar electrokinetic chromatography method for the quantitation of dexamethasone, ondansetron and aprepitant, antiemetic drugs, in organogel.
Bourdon F; Lecoeur M; Duhaut M; Odou P; Vaccher C; Foulon C
J Pharm Biomed Anal; 2013 Dec; 86():40-8. PubMed ID: 23978340
[TBL] [Abstract][Full Text] [Related]
8. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
9. Preparation and in vitro evaluation of a pluronic lecithin organogel containing ricinoleic acid for transdermal delivery.
Boddu SH; Bonam SP; Wei Y; Alexander K
Int J Pharm Compd; 2014; 18(3):256-61. PubMed ID: 25306775
[TBL] [Abstract][Full Text] [Related]
10. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer.
Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S
Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114
[TBL] [Abstract][Full Text] [Related]
12. Complementarity of UV-PLS and HPLC for the simultaneous evaluation of antiemetic drugs.
Bourdon F; Lecoeur M; Odou P; Vaccher C; Foulon C
Talanta; 2014 Mar; 120():274-82. PubMed ID: 24468370
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
16. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
17. Microemulsion as a tool for the transdermal delivery of ondansetron for the treatment of chemotherapy induced nausea and vomiting.
Al Abood RM; Talegaonkar S; Tariq M; Ahmad FJ
Colloids Surf B Biointerfaces; 2013 Jan; 101():143-51. PubMed ID: 22796784
[TBL] [Abstract][Full Text] [Related]
18. Development and in-vivo evaluation of ondansetron gels for transdermal delivery.
Patel DR; Joshi A; Patel HH; Stagni G
Drug Dev Ind Pharm; 2015 Jun; 41(6):1030-6. PubMed ID: 24919508
[TBL] [Abstract][Full Text] [Related]
19. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Tanimura S; Banba J; Tomoyasu H; Masaki M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
[TBL] [Abstract][Full Text] [Related]
20. Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting.
Svanberg A; Birgegård G
Oncology; 2015; 89(1):31-6. PubMed ID: 25659986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]